EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design

Lars H Lund iD, Stefan James, Adam D DeVore, Kevin J Anstrom, Marat Fudim, Keith D Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L Fleg, Song Yang, Michael Fu, Camilla Hage und 10 weitere

European Journal of Heart Failure · 2024

DOI: 10.1002/ejhf.3453 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Lars H Lund und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Karolinska Institutet, Sweden. Hauptthemen laut MEDLINE: Heart Failure, Spironolactone, Stroke Volume, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.

Methods

SPIRRIT-HFpEF is a multicentre, prospective, randomized, open-label, blinded endpoint trial conducted on platforms in the Swedish Heart Failure Registry (SwedeHF) and the United States (US) Trial Innovation Network. Patients with HFpEF/HFmrEF are randomized 1:1 to spironolactone (or eplerenone) in addition to usual care, versus usual care alone. The primary outcome is total number of cardiovascular deaths and hospitalizations for heart failure. Outcomes are collected from Swedish administrative complete coverage registries and a US call centre and subsequently adjudicated. Simple eligibility criteria were based on data available in SwedeHF: heart failure as outpatient or at discharge from hospital, left ventricular ejection fraction ≥40%, N-terminal pro-B-type natriuretic peptide >300 ng/L (in sinus rhythm) or >750 ng/L (in atrial fibrillation), with pre-specified adjustment for elevated body mass index, and chronic loop diuretic use. Power and sample size assessments were based on an event-driven design allowing enrolment over approximately 6 years, and application of hazard ratios from the TOPCAT trial, Americas subset. The final sample size is expected to be approximately 2400 patients.

Conclusion

SPIRRIT-HFpEF will be informative on the effectiveness of generic MRAs in HFpEF and HFmrEF, and on the feasibility of conducting pragmatic and registry-based trials in heart failure and other chronic conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSpironolactoneStroke VolumeMineralocorticoid Receptor AntagonistsRegistriesHumansSwedenProspective StudiesUnited StatesFemaleMaleAgedMulticenter Studies as TopicRandomized Controlled Trials as TopicPragmatic Clinical Trials as Topic

Stichwörter der Autor:innen

AldosteroneEplerenoneHeart failure with mildly reduced ejection fractionHeart failure with preserved ejection fractionMineralocorticoid receptor antagonistsPragmatic trialRegistry‐based randomized clinical trialSpironolactone

Substanzen

SpironolactoneMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Medicine, Karolinska Institutet, Sweden.
  • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Uppsala Clinical Research Center and Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Lars H Lund

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Lund, L. H., James, S., DeVore, A. D., Anstrom, K. J., Fudim, M., Aaronson, K. D., Dahlström, U., Desvigne-Nickens, P., Fleg, J. L., Yang, S., Fu, M., Hage, C., Held, C., Karlström, P., Nygren, M., Peterson, E. D., Pol, T., Sapp, S., Sundström, J., …, & Pitt, B. (2024). The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3453

Vancouver

Lund LH, James S, DeVore AD, Anstrom KJ, Fudim M, Aaronson KD, et al. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3453

BibTeX
@article{Lund2024,
  author = {Lund, Lars H and James, Stefan and DeVore, Adam D and Anstrom, Kevin J and Fudim, Marat and Aaronson, Keith D and Dahlström, Ulf and Desvigne-Nickens, Patrice and Fleg, Jerome L and Yang, Song and Fu, Michael and Hage, Camilla and Held, Claes and Karlström, Patric and Nygren, Magnus and Peterson, Eric D and Pol, Tymon and Sapp, Shelly and Sundström, Johan and Östlund, Ollie and Oldgren, Jonas and Pitt, Bertram},
  title = {The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and Design},
  journal = {European Journal of Heart Failure},
  year = {2024},
  doi = {10.1002/ejhf.3453}
}
Kostenlos starten →